Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc. (NASDAQ:VRDN) is one of the 10 oversold small cap stocks to buy now.

On April 21, Truist reduced the price target on Viridian Therapeutics Inc. (NASDAQ:VRDN) from $36 to $33 while maintaining a Buy rating on the stock. Despite the downward revision in target price, the stock still offers an attractive upside potential of more than 140%, making it one of the best oversold small-cap names.

Likoper/Shutterstock.com

The firm is modifying its model based on revised assumptions around volume and pricing, keeping in mind a possible launch of Veli for both acute and chronic thyroid eye disease. It continues to hold positive sentiment towards the stock due to the visible catalysts ahead.

On April 8, Laura Chico from Wedbush maintained an Outperform rating for Viridian Therapeutics Inc. (NASDAQ:VRDN) while reducing the target price from $37 to $31. The analyst noted that over the past several years, the company has effectively managed a number of competitive threats in the industry.

However, Chico cautions that, in light of a recent pipeline update from Amgen on its Tepezza on-body injector, careful market observation is necessary. Using this different administration method, Amgen Inc. (NASDAQ:AMGN) reported a strong 57% placebo-adjusted proptosis response. Laura believes that the impending release of positive REVEAL-2 clinical results will continue to be the major catalyst for elegrobart’s value. For the second quarter of 2026, this crucial pipeline milestone is still well on schedule.

Viridian Therapeutics Inc. (NASDAQ:VRDN) is involved in discovering and selling treatments for rare and serious illnesses. It produces three main therapeutics, which include Veligrotrug, Elegrobart, and anti-thyroid-stimulating hormone receptor (TSHR). Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-008 and VRDN-006.

While we acknowledge the risk and potential of VRDN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRDN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.